Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

Intellia Therapeutics said on Monday it has temporarily stopped dosing and screening patients in two late-stage studies of its gene-editing treatment for a heart condition after a patient developed ...

Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z. ・The ...

Shares of Intellia sank after the company paused patient dosing and screening for trials of its nex-z drug after on participant in the study reported signs of liver injury. The stock fell 46% to ...

Alecensa (alectinib) demonstrated a 22% reduction in the risk of death compared with Xalkori (crizotinib) in the frontline ...

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...

Intellia Therapeutics temporarily paused patient dosing and screening for trials of its nex-z drug after a patient dosed with the drug reported signs of liver injury. The drug is intended to treat ...

Intellia Therapeutics has temporarily paused dosing and screening for its phase 3 Magnitude and Magnitude-2 trials of Nex-z following a patient hospitalization, according to an Oct. 27 news release.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...

Intellia Therapeutics (NASDAQ:NTLA) stock tumbled 50% Monday after the company announced it has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a ...

With lifestyle disorders and non-communicable diseases on the rise, many people routinely undergo Liver Function Tests (LFTs) ...

Leerink notes that Intellia Therapeutics (NTLA) announced a protocol-specified pause of Phase 3 MAGNITUDE and MAGNITUDE-2 studies of nex-z in ...